

1: Le XF, Lammayot A, Gold D, Lu Y, Mao W, Chang T, Patel A, Mills GB, Bast RC Jr.

Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling.

J Biol Chem. 2005 Jan 21;280(3):2092-104. Epub 2004 Oct 25.

PMID: 15504738 [PubMed - indexed for MEDLINE]

2: Kuwada SK, Scaife CL, Kuang J, Li X, Wong RF, Florell SR, Coffey RJ Jr, Gray PD.

Effects of trastuzumab on epidermal growth factor receptor-dependent and -independent human colon cancer cells.

Int J Cancer. 2004 Mar 20;109(2):291-301.

PMID: 14750183 [PubMed - indexed for MEDLINE]

3: Berezov A, Greene MI, Murali R.

Structure-based approaches to inhibition of erbB receptors with peptide mimetics.

Immunol Res. 2003;27(2-3):303-8. Review.

PMID: 12857977 [PubMed - indexed for MEDLINE]

4: Le XF, Claret FX, Lammayot A, Tian L, Deshpande D, LaPushin R, Tari AM, Bast RC Jr.

The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition.

J Biol Chem. 2003 Jun 27;278(26):23441-50. Epub 2003 Apr 16.

PMID: 12700233 [PubMed - indexed for MEDLINE]

5: Talukder AH, Bagheri-Yarmand R, Williams RR, Ragoussis J, Kumar R, Raz A.

Antihuman epidermal growth factor receptor 2 antibody herceptin inhibits autocrine motility factor (AMF) expression and potentiates antitumor effects of AMF inhibitors.

Clin Cancer Res. 2002 Oct;8(10):3285-9.

PMID: 12374700 [PubMed - indexed for MEDLINE]

6: Bergman I, Barmada MA, Griffin JA, Slamon DJ.

Treatment of meningeal breast cancer xenografts in the rat using an anti-p185/HER2 antibody.

Clin Cancer Res. 2001 Jul;7(7):2050-6.

PMID: 11448923 [PubMed - indexed for MEDLINE]

7: Willuda J, Kubetzko S, Waibel R, Schubiger PA, Zangemeister-Wittke U, Pluckthun A.

Tumor targeting of mono-, di-, and tetravalent anti-p185(HER-2) miniantibodies multimerized by self-associating peptides.

J Biol Chem. 2001 Apr 27;276(17):14385-92. Epub 2001 Jan 22.

PMID: 11278961 [PubMed - indexed for MEDLINE]

8: Tsai SW, Sun Y, Williams LE, Raubitschek AA, Wu AM, Shively JE.

Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5.

Bioconjug Chem. 2000 May-Jun;11(3):327-34.

PMID: 10821648 [PubMed - indexed for MEDLINE]

1: 1FVED
Chain D, X-Ray Structures Of The Antigen-Binding Domains From Three Variants Of Humanized Anti-P185her2 Antibody 4d5 And Comparison With Molecular Modeling
gi|442926|pdb|1FVE|D[442926]

2: 1FVEC
Chain C, X-Ray Structures Of The Antigen-Binding Domains From Three Variants Of Humanized Anti-P185her2 Antibody 4d5 And Comparison With Molecular Modeling
gi|442925|pdb|1FVE|C[442925]

3: 1FVEB
Chain B, X-Ray Structures Of The Antigen-Binding Domains From Three Variants Of Humanized Anti-P185her2 Antibody 4d5 And Comparison With Molecular Modeling
gi|442924|pdb|1FVE|B[442924]

4: 1FVEA
Chain A, X-Ray Structures Of The Antigen-Binding Domains From Three Variants Of Humanized Anti-P185her2 Antibody 4d5 And Comparison With Molecular Modeling
gi|442923|pdb|1FVE|A[442923]

5: 1FVDD
Chain D, Fab Fragment Of Humanized Antibody 4d5, Version 4
gi|442922|pdb|1FVD|D[442922]

6: 1FVDC
Chain C, Fab Fragment Of Humanized Antibody 4d5, Version 4
gi|442921|pdb|1FVD|C[442921]

7: 1FVDB
Chain B, Fab Fragment Of Humanized Antibody 4d5, Version 4
gi|442920|pdb|1FVD|B[442920]

8: 1FVDA
Chain A, Fab Fragment Of Humanized Antibody 4d5, Version 4
gi|442919|pdb|1FVD|A[442919]

9: 1FVCD
Chain D, Fv Fragment Of Humanized Antibody 4d5, Version 8
gi|442918|pdb|1FVC|D[442918]

10: 1FVCC
Chain C, Fv Fragment Of Humanized Antibody 4d5, Version 8
gi|442917|pdb|1FVC|C[442917]

11: 1FVCB
Chain B, Fv Fragment Of Humanized Antibody 4d5, Version 8
gi|442916|pdb|1FVC|B[442916]

- 1: Zhang WY, Yip TC, Kwok CS.
Rapid purification of a new humanized single-chain Fv antibody/human interleukin-2 fusion protein reactive against HER2 receptor.
Acta Biochim Biophys Sin (Shanghai). 2004 Oct;36(10):707-12.
PMID: 15483752 [PubMed - indexed for MEDLINE]

- 2: Repp R, van Ojik HH, Valerius T, Groenewegen G, Wieland G, Oetzel C, Stockmeyer B, Becker W, Eisenhut M, Steininger H, Deo YM, Blijham GH, Kalden JR, van de Winkel JG, Gramatzki M.
Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer.
Br J Cancer. 2003 Dec 15;89(12):2234-43.
PMID: 14676800 [PubMed - indexed for MEDLINE]

- 3: Baral R, Sherrat A, Das R, Foon KA, Bhattacharya-Chatterjee M.
Murine monoclonal anti-idiotypic antibody as a surrogate antigen for human Her-2/neu.
Int J Cancer. 2001 Apr 1;92(1):88-95.
PMID: 11279611 [PubMed - indexed for MEDLINE]

- 4: Schmidt M, McWatters A, White RA, Groner B, Wels W, Fan Z, Bast RC Jr.
Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2.
Gynecol Oncol. 2001 Feb;80(2):145-55.
PMID: 11161852 [PubMed - indexed for MEDLINE]

- 5: Keler T, Guyre PM, Vitale LA, Sundarapandian K, van De Winkel JG, Deo YM, Graziano RF.
Targeting weak antigens to CD64 elicits potent humoral responses in human CD64 transgenic mice.
J Immunol. 2000 Dec 15;165(12):6738-42.
PMID: 11120792 [PubMed - indexed for MEDLINE]

- 6: Garcia de Palazzo I, Klein-Szanto A, Weiner LM.
Immunohistochemical detection of c-erbB-2 expression by neoplastic human tissue using monospecific and bispecific monoclonal antibodies.
Int J Biol Markers. 1993 Oct-Dec;8(4):233-9.
PMID: 7908024 [PubMed - indexed for MEDLINE]

- 7: Weiner LM, Holmes M, Adams GP, LaCreta F, Watts P, Garcia de Palazzo I.
A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
Cancer Res. 1993 Jan 1;53(1):94-100.
PMID: 8093231 [PubMed - indexed for MEDLINE]